Click here to get full coverage on After six complete responses, Tempest brings updated CAR-T data to Dublin - Stock Titan

After six complete responses, Tempest brings updated CAR-T data to Dublin  Stock Titan

After six complete responses, Tempest brings updated CAR-T data to Dublin - Stock Titan

Click here to get full coverage on Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting - GlobeNewswire

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting  GlobeNewswire

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting - GlobeNewswire

Click here to get full coverage on Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - Yahoo Finance

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T  Yahoo Finance

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - Yahoo Finance

Click here to get full coverage on $TPST stock is up 28% today. Here's what we see in our data. - Quiver Quantitative

$TPST stock is up 28% today. Here's what we see in our data.  Quiver Quantitative

$TPST stock is up 28% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - MSN

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction  MSN

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - MSN

Click here to get full coverage on TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - Stocktwits

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction  Stocktwits

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - Stocktwits

Click here to get full coverage on Tempest brings in China dealmaker for Phase 3-ready cancer drug - Stock Titan

Tempest brings in China dealmaker for Phase 3-ready cancer drug  Stock Titan

Tempest brings in China dealmaker for Phase 3-ready cancer drug - Stock Titan

Click here to get full coverage on Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement - Stock Titan

Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement  Stock Titan

Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement - Stock Titan

Click here to get full coverage on After 6 of 6 complete responses, Tempest moves toward pivotal CAR-T study - Stock Titan

After 6 of 6 complete responses, Tempest moves toward pivotal CAR-T study  Stock Titan

After 6 of 6 complete responses, Tempest moves toward pivotal CAR-T study - Stock Titan

Click here to get full coverage on Tempest myeloma cell therapy hits 100% response in 25 patients, US trial planned - Stock Titan

Tempest myeloma cell therapy hits 100% response in 25 patients, US trial planned  Stock Titan

Tempest myeloma cell therapy hits 100% response in 25 patients, US trial planned - Stock Titan

Click here to get full coverage on Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 - GlobeNewswire

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026  GlobeNewswire

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 - GlobeNewswire

Click here to get full coverage on [EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan

[EFFECT] Tempest Therapeutics, Inc. SEC Filing  Stock Titan

[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan

Click here to get full coverage on Cancer biotech Tempest retools around dual CAR-Ts and new CEO - Stock Titan

Cancer biotech Tempest retools around dual CAR-Ts and new CEO  Stock Titan

Cancer biotech Tempest retools around dual CAR-Ts and new CEO - Stock Titan

Click here to get full coverage on Cancer drug developer Tempest to hand out 1:1 stock warrants - Stock Titan

Cancer drug developer Tempest to hand out 1:1 stock warrants  Stock Titan

Cancer drug developer Tempest to hand out 1:1 stock warrants - Stock Titan

Click here to get full coverage on Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 - Yahoo Finance

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026  Yahoo Finance

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 - Yahoo Finance

Click here to get full coverage on Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers - Stock Titan

Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers  Stock Titan

Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers - Stock Titan

Click here to get full coverage on Partner-funded China trials anchor Tempest’s new CAR-T push - Stock Titan

Partner-funded China trials anchor Tempest’s new CAR-T push  Stock Titan

Partner-funded China trials anchor Tempest’s new CAR-T push - Stock Titan

Click here to get full coverage on Tempest's new CEO arrives as six myeloma patients hit complete response - Stock Titan

Tempest's new CEO arrives as six myeloma patients hit complete response  Stock Titan

Tempest's new CEO arrives as six myeloma patients hit complete response - Stock Titan

Click here to get full coverage on Tempest (Nasdaq: TPST) to buy CD19/BCMA Dual-CAR T assets, runway to mid 2027 - Stock Titan

Tempest (Nasdaq: TPST) to buy CD19/BCMA Dual-CAR T assets, runway to mid 2027  Stock Titan

Tempest (Nasdaq: TPST) to buy CD19/BCMA Dual-CAR T assets, runway to mid 2027 - Stock Titan

Click here to get full coverage on Factor Bioscience tied to Tempest (NASDAQ: TPST) CEO buys 231,482 shares - Stock Titan

Factor Bioscience tied to Tempest (NASDAQ: TPST) CEO buys 231,482 shares  Stock Titan

Factor Bioscience tied to Tempest (NASDAQ: TPST) CEO buys 231,482 shares - Stock Titan

Click here to get full coverage on Matthew Angel’s 37.4% Tempest (NASDAQ: TPST) stake tied to asset deal, private placement - Stock Titan

Matthew Angel’s 37.4% Tempest (NASDAQ: TPST) stake tied to asset deal, private placement  Stock Titan

Matthew Angel’s 37.4% Tempest (NASDAQ: TPST) stake tied to asset deal, private placement - Stock Titan

Click here to get full coverage on Tempest Therapeutics provides update on development of TPST-2003 - TipRanks

Tempest Therapeutics provides update on development of TPST-2003  TipRanks

Tempest Therapeutics provides update on development of TPST-2003 - TipRanks

Click here to get full coverage on Tempest Therapeutics (Nasdaq: TPST) details $2.0 million private placement deal - Stock Titan

Tempest Therapeutics (Nasdaq: TPST) details $2.0 million private placement deal  Stock Titan

Tempest Therapeutics (Nasdaq: TPST) details $2.0 million private placement deal - Stock Titan

Click here to get full coverage on TPST Q4'25 Earnings: EPS estimate is (0.62) USD - TradingView

TPST Q4'25 Earnings: EPS estimate is (0.62) USD  TradingView

TPST Q4'25 Earnings: EPS estimate is (0.62) USD - TradingView

Click here to get full coverage on Tempest Therapeutics (TPST) CFO receives 140,000 stock options at $1.64 - Stock Titan

Tempest Therapeutics (TPST) CFO receives 140,000 stock options at $1.64  Stock Titan

Tempest Therapeutics (TPST) CFO receives 140,000 stock options at $1.64 - Stock Titan

Click here to get full coverage on Tempest Therapeutics Reports Q3 2025 Financial Results and Strategic Update on Clinical Developments - Quiver Quantitative

Tempest Therapeutics Reports Q3 2025 Financial Results and Strategic Update on Clinical Developments  Quiver Quantitative

Tempest Therapeutics Reports Q3 2025 Financial Results and Strategic Update on Clinical Developments - Quiver Quantitative

Click here to get full coverage on Why Tempest Therapeutics (TPST) Stock Is Down 45% Today - Benzinga

Why Tempest Therapeutics (TPST) Stock Is Down 45% Today  Benzinga

Why Tempest Therapeutics (TPST) Stock Is Down 45% Today - Benzinga

Click here to get full coverage on Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller - Stock Titan

Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller  Stock Titan

Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller - Stock Titan

Click here to get full coverage on Tempest Therapeutics outlines plans for acquired CAR T assets - BioWorld News

Tempest Therapeutics outlines plans for acquired CAR T assets  BioWorld News

Tempest Therapeutics outlines plans for acquired CAR T assets - BioWorld News

Click here to get full coverage on Tempest’s third makeover | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Tempest’s third makeover | ApexOnco - Clinical Trials news and analysis  Oncology Pipeline

Tempest’s third makeover | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Click here to get full coverage on Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO - Fierce Biotech

Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO  Fierce Biotech

Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO - Fierce Biotech

Click here to get full coverage on Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - GlobeNewswire

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets  GlobeNewswire

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - GlobeNewswire

Click here to get full coverage on H.C. Wainwright upgrades Tempest Therapeutics stock rating to Buy with $11 target - Investing.com

H.C. Wainwright upgrades Tempest Therapeutics stock rating to Buy with $11 target  Investing.com

H.C. Wainwright upgrades Tempest Therapeutics stock rating to Buy with $11 target - Investing.com

Click here to get full coverage on Tempest Reports Year End 2025 Financial Results and Provides Business Update - GlobeNewswire

Tempest Reports Year End 2025 Financial Results and Provides Business Update  GlobeNewswire

Tempest Reports Year End 2025 Financial Results and Provides Business Update - GlobeNewswire

Click here to get full coverage on Tempest Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview - TradingView

Tempest Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview  TradingView

Tempest Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview - TradingView

Click here to get full coverage on Tempest Therapeutics stock surges after H.C. Wainwright upgrade - Investing.com

Tempest Therapeutics stock surges after H.C. Wainwright upgrade  Investing.com

Tempest Therapeutics stock surges after H.C. Wainwright upgrade - Investing.com

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST) - The Globe and Mail

Click here to get full coverage on Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets - GlobeNewswire

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets  GlobeNewswire

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets - GlobeNewswire

Click here to get full coverage on President Prabowo praises Banyumas TPST as national waste model - ANTARA News

President Prabowo praises Banyumas TPST as national waste model  ANTARA News

President Prabowo praises Banyumas TPST as national waste model - ANTARA News

Click here to get full coverage on Tempest Announces Strategic Acquisition of New Dual-CAR T - GlobeNewswire

Tempest Announces Strategic Acquisition of New Dual-CAR T  GlobeNewswire

Tempest Announces Strategic Acquisition of New Dual-CAR T - GlobeNewswire

Click here to get full coverage on Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition - FinancialContent

Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition  FinancialContent

Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition - FinancialContent

Click here to get full coverage on Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update  Yahoo Finance

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Click here to get full coverage on Tempest gains CAR Ts for 65% of the company; stock drops - BioWorld News

Tempest gains CAR Ts for 65% of the company; stock drops  BioWorld News

Tempest gains CAR Ts for 65% of the company; stock drops - BioWorld News

Click here to get full coverage on Reactivating 6 Landfills, the Bandung City Environment Agency Aims to Process 450 Tons of Waste per Day - Jabarprov

Reactivating 6 Landfills, the Bandung City Environment Agency Aims to Process 450 Tons of Waste per Day  Jabarprov

Reactivating 6 Landfills, the Bandung City Environment Agency Aims to Process 450 Tons of Waste per Day - Jabarprov

Click here to get full coverage on Tempest Therapeutics Raises $2.0 Million in Private Placement With Warrants Priced at $2.16 - TradingView

Tempest Therapeutics Raises $2.0 Million in Private Placement With Warrants Priced at $2.16  TradingView

Tempest Therapeutics Raises $2.0 Million in Private Placement With Warrants Priced at $2.16 - TradingView

Click here to get full coverage on Tempest Therapeutics to acquire Factor Bioscience’s CAR-T programs - Investing.com

Tempest Therapeutics to acquire Factor Bioscience’s CAR-T programs  Investing.com

Tempest Therapeutics to acquire Factor Bioscience’s CAR-T programs - Investing.com

Click here to get full coverage on Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders - GlobeNewswire

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders  GlobeNewswire

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders - GlobeNewswire

Click here to get full coverage on Tempest Therapeutics Signs Warrant Agreement With Computershare - TradingView

Tempest Therapeutics Signs Warrant Agreement With Computershare  TradingView

Tempest Therapeutics Signs Warrant Agreement With Computershare - TradingView

Click here to get full coverage on Angel Matthew, CEO and president, buys Tempest Therapeutics shares for $500k - Investing.com

Angel Matthew, CEO and president, buys Tempest Therapeutics shares for $500k  Investing.com

Angel Matthew, CEO and president, buys Tempest Therapeutics shares for $500k - Investing.com

Click here to get full coverage on Tempest Therapeutics 10-K: Net loss $26.3M, EPS $(6.33) - TradingView

Tempest Therapeutics 10-K: Net loss $26.3M, EPS $(6.33)  TradingView

Tempest Therapeutics 10-K: Net loss $26.3M, EPS $(6.33) - TradingView

Click here to get full coverage on Tempest Therapeutics stock plunges after all-stock acquisition - Investing.com

Tempest Therapeutics stock plunges after all-stock acquisition  Investing.com

Tempest Therapeutics stock plunges after all-stock acquisition - Investing.com

Click here to get full coverage on Tempest Therapeutics Announces Up To $6 Million Private Placement - GlobeNewswire

Tempest Therapeutics Announces Up To $6 Million Private Placement  GlobeNewswire

Tempest Therapeutics Announces Up To $6 Million Private Placement - GlobeNewswire

Click here to get full coverage on Can Tempest Therapeutics (TPST) Stock Maintain Growth | Price at $1.79, Up 13.29% - Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La

Can Tempest Therapeutics (TPST) Stock Maintain Growth | Price at $1.79, Up 13.29% - Community Chart Signals  Cổng thông tin điện tử Tỉnh Sơn La

Can Tempest Therapeutics (TPST) Stock Maintain Growth | Price at $1.79, Up 13.29% - Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La

Click here to get full coverage on Encourage Integrated Waste Management and National Circular Economy, President Prabowo Reviews TPST BLE Banyumas - VOI.id

Encourage Integrated Waste Management and National Circular Economy, President Prabowo Reviews TPST BLE Banyumas  VOI.id

Encourage Integrated Waste Management and National Circular Economy, President Prabowo Reviews TPST BLE Banyumas - VOI.id

Click here to get full coverage on Tempest Therapeutics completes acquisition of CAR-T assets - Investing.com

Tempest Therapeutics completes acquisition of CAR-T assets  Investing.com

Tempest Therapeutics completes acquisition of CAR-T assets - Investing.com

Click here to get full coverage on Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - Yahoo Finance

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets  Yahoo Finance

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - Yahoo Finance

Click here to get full coverage on Tempest Therapeutics Announces New Leadership and Acquisition - TipRanks

Tempest Therapeutics Announces New Leadership and Acquisition  TipRanks

Tempest Therapeutics Announces New Leadership and Acquisition - TipRanks

Click here to get full coverage on Tempest Therapeutics Announces Record Date for Warrant Dividends Distribution Following Asset Purchase Agreement - Quiver Quantitative

Tempest Therapeutics Announces Record Date for Warrant Dividends Distribution Following Asset Purchase Agreement  Quiver Quantitative

Tempest Therapeutics Announces Record Date for Warrant Dividends Distribution Following Asset Purchase Agreement - Quiver Quantitative

Click here to get full coverage on Can Tempest Therapeutics (TPST) Stock Maintain Growth | Price at $1.79, Up 13.29% - Volatility Analysis - Cổng thông tin điện tử tỉnh Lào Cai

Can Tempest Therapeutics (TPST) Stock Maintain Growth | Price at $1.79, Up 13.29% - Volatility Analysis  Cổng thông tin điện tử tỉnh Lào Cai

Can Tempest Therapeutics (TPST) Stock Maintain Growth | Price at $1.79, Up 13.29% - Volatility Analysis - Cổng thông tin điện tử tỉnh Lào Cai

Click here to get full coverage on Market Movers | Winners: WSHP, SGBX, SEMR | Losers: IVP, AGIO, TPST - Trefis

Market Movers | Winners: WSHP, SGBX, SEMR | Losers: IVP, AGIO, TPST  Trefis

Market Movers | Winners: WSHP, SGBX, SEMR | Losers: IVP, AGIO, TPST - Trefis

Click here to get full coverage on Key facts: Tempest Therapeutics announces management changes; issues warrants - TradingView

Key facts: Tempest Therapeutics announces management changes; issues warrants  TradingView

Key facts: Tempest Therapeutics announces management changes; issues warrants - TradingView

Click here to get full coverage on Tempest Therapeutics, Inc. Completes Registered Direct Offering and Private Placement, Raising Approximately $4.25 Million - Quiver Quantitative

Tempest Therapeutics, Inc. Completes Registered Direct Offering and Private Placement, Raising Approximately $4.25 Million  Quiver Quantitative

Tempest Therapeutics, Inc. Completes Registered Direct Offering and Private Placement, Raising Approximately $4.25 Million - Quiver Quantitative

Click here to get full coverage on Tempest Therapeutics Overhauls Leadership and Acquires New Assets - TipRanks

Tempest Therapeutics Overhauls Leadership and Acquires New Assets  TipRanks

Tempest Therapeutics Overhauls Leadership and Acquires New Assets - TipRanks

Click here to get full coverage on Tempest Therapeutics receives Nasdaq notice for annual meeting compliance - Investing.com

Tempest Therapeutics receives Nasdaq notice for annual meeting compliance  Investing.com

Tempest Therapeutics receives Nasdaq notice for annual meeting compliance - Investing.com

Click here to get full coverage on New Strong Buy Stocks for April 10th - Yahoo Finance

New Strong Buy Stocks for April 10th  Yahoo Finance

New Strong Buy Stocks for April 10th - Yahoo Finance

Click here to get full coverage on What date does Tempest Therapeutics's (TPST) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research

What date does Tempest Therapeutics's (TPST) report Earnings - Earnings Calendar & Announcement  Zacks Investment Research

What date does Tempest Therapeutics's (TPST) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research

Click here to get full coverage on Should I buy Tempest Therapeutics (TPST) - Zacks Investment Research

Should I buy Tempest Therapeutics (TPST)  Zacks Investment Research

TPST

Price Chart

Key Statistics

Technicals

About TPST

Latest News

After six complete responses, Tempest brings updated CAR-T data to Dublin - Stock Titan

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting - GlobeNewswire

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers